恩替卡韦联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化80例疗效观察

发布时间：2019-05-23 10:39

【摘要】：目的探究恩替卡韦(entecavir,ETV)联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化的临床疗效。方法选取慢性乙型肝炎肝纤维化患者160例,随机分为2组。对照组80例,采用单一ETV治疗,联合组80例,采用ETV联合肝复乐胶囊治疗,疗程均为3个月。观察两组患者治疗前和治疗后肝功指标、乙型肝炎病毒血清学标志物、HBV DNA载量、肝纤维化指标及肝脏影像学等变化。结果治疗后,联合组ALT水平、HBe Ag血清学转换率、肝纤维化指标(HA、LN、PC-Ⅲ、Ⅳ-C)、门静脉内径及脾脏厚度均显著低于对照组(P值分别为0.0048、0.0001、0.0019、0.0043、0.0017、0.0002、0.0025和0.0020);HBV DNA低于检测下限率、AST、TBil、ALB、PT与对照组相比无统计学差异(P值分别为1.2922、0.0598、0.0751、0.0972和0.9916)。结论采用ETV结合肝复乐胶囊联合治疗慢性乙型肝炎肝纤维化临床效果良好,值得广泛推广应用。
[Abstract]:Objective to investigate the clinical effect of entecavir (entecavir,ETV) combined with Ganfule capsule in the treatment of chronic hepatitis B liver fibrosis. Methods 160 patients with chronic hepatitis B hepatic fibrosis were randomly divided into two groups. 80 cases in the control group were treated with single ETV and 80 cases in the combined group were treated with ETV combined with Ganfule capsule for 3 months. The changes of liver function index, hepatitis B virus serological marker, HBV DNA load, hepatic fibrosis index and liver imaging were observed before and after treatment. Results after treatment, the serological conversion rate of, HBe Ag at ALT level and the index of hepatic fibrosis (HA,LN,PC- III, IV-C),) in the combined group were compared with those in the control group. The inner diameter of portal vein and the thickness of spleen were significantly lower than those of the control group (P = 0.0048, 0.0001, 0.0019, 0.0043, 0.0017, 0.002, 0.0025 and 0.0020, respectively). HBV DNA was lower than the lower limit rate, and there was no significant difference in AST,TBil,ALB,PT between the control group and the control group (P = 1.2922, 0.0598, 0.0751, 0.0972 and 0.9916, respectively). Conclusion ETV combined with Ganfule capsule is effective in the treatment of chronic hepatitis B liver fibrosis and is worth popularizing and applying widely.
【作者单位】：呼和浩特市第二(传染病)医院科教科;呼和浩特市第二(传染病)医院检验科;
【分类号】：R512.62;R575.2

【相似文献】